Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (RAVE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00104299 |
|
Recruitment Status :
Completed
First Posted : February 25, 2005
Results First Posted : August 25, 2011
Last Update Posted : April 21, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA.
Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Vasculitis Wegener's Granulomatosis Microscopic Polyangiitis | Drug: Rituximab plus cyclophosphamide placebo (rituximab group) Drug: Cyclophosphamide plus rituximab placebo (control group) Drug: Azathioprine Drug: Methylprednisolone (or other glucocorticoid) Drug: Prednisone | Phase 2 Phase 3 |
Current conventional therapies for ANCA-associated vasculitis (AAV) are associated with high incidences of treatment failure, disease relapse, substantial toxicity, and patient morbidity and mortality. Rituximab is a monoclonal antibody used to treat non-Hodgkin's lymphoma. This study will evaluate the efficacy of rituximab with glucocorticoids in inducing disease remission in patients with severe forms of AAV (WG and MPA).
The study consists of two phases: a 6-month remission induction phase, followed by a 12-month remission maintenance phase. All participants will receive at least 1 g of pulse intravenous methylprednisolone or a dose-equivalent of another glucocorticoid preparation. Depending on the participant's condition, he or she may receive up to 3 days of intravenous methylprednisolone for a total of 3 g of methylprednisolone (or a dose-equivalent). During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
Next, participants will be randomly assigned to one of two arms. Arm 1 participants will receive rituximab (375 mg/m^2) infusions once weekly for 4 weeks and cyclophosphamide (CYC) placebo daily for 3 to 6 months. Arm 2 participants will receive rituximab placebo infusions once weekly for 4 weeks and CYC daily for 3 to 6 months. During the remission maintenance phase, participants in Arm 1 will discontinue CYC placebo and start oral azathioprine (AZA) placebo daily until Month 18. Participants in Arm 2 will discontinue CYC and start AZA daily until Month 18. Participants who fail treatment before Month 6 will be crossed over to the other treatment arm unless there are specific contraindications. Participants in either group who reach clinical remission before they complete 6 months of therapy may switch from CYC/placebo to AZA/placebo if directed by their physicians.
All participants will be followed for at least 18 months. Initially, study visits are weekly, progressing to monthly and then quarterly visits as the study proceeds. Blood collection will occur at each study visit.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 197 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) |
| Study Start Date : | January 2005 |
| Actual Primary Completion Date : | December 2008 |
| Actual Study Completion Date : | January 2010 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Rituximab |
Drug: Rituximab plus cyclophosphamide placebo (rituximab group)
375 mg/m^2 infusions once weekly for 4 week
Other Name: Rituxan Drug: Methylprednisolone (or other glucocorticoid) 1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
Other Name: Medrol Drug: Prednisone During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
Other Name: Deltasone, Liquid Pred, Meticorten, Orasone |
| Active Comparator: Control Group |
Drug: Cyclophosphamide plus rituximab placebo (control group)
2 mg/kg/day orally for months 1-3
Other Name: Cytoxan Drug: Azathioprine 2 mg/kg/day orally for months 4-6
Other Name: imuran Drug: Methylprednisolone (or other glucocorticoid) 1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
Other Name: Medrol Drug: Prednisone During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
Other Name: Deltasone, Liquid Pred, Meticorten, Orasone |
- Disease Remission [ Time Frame: 6 months post-randomization ]A Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) score of 0 with prednisone taper successfully completed at six months. The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease.
- Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy [ Time Frame: Through common close-out (defined as 18 months after the last participant is enrolled in the trial) ]The adverse event rate for the following events considered related to vasculitis: Death; Grade 2 or higher leukopenia or thrombocytopenia; Grade 3 or higher infections; Hemorrhagic cystitis (grade 2 or lower needs confirmation by cytoscopy); Malignancy; Venous thromboembolic event (deep venous thrombosis or pulmonary embolism); Hospitalization resulting either from the disease or from a complication due to study treatment; Infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions (including cytokine release allergic reaction); Cerebrovascular accident
- Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization [ Time Frame: 6 months post-randomization ]
The 2-sided 95% CI of the percentage of participants who have a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and have successfully completed the glucocorticoid taper by 6 months post-randomization and the 2-sided 95% CI of the difference between two arms for assessing the superiority of rituximab to control
[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease
- The Duration of Complete Remission (BVAS=0, Off Glucocorticoids), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups [ Time Frame: 18 months post-randomization ]
Duration of complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of Prednisone to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing.
[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease
- The Duration of Remission (BVAS=0), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups [ Time Frame: 18 months post-randomization ]Duration of remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of glucocorticoid by 6 months post-randomization to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing.
- Time to Remission (BVAS=0) From the Visit 1 Baseline Visit in the Two Treatment Groups [ Time Frame: 18 months post-randomization ]
Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0.
[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease
- Time to Complete Remission (BVAS=0, Off Glucocorticoids) From the Visit 1 Baseline Visit in the Two Treatment Groups [ Time Frame: 18 months post-randomization ]
Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and completing taper of glucocorticoid by 6 months post-randomization.
[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Weight of at least 88 pounds(40 kilograms)
- Diagnosis of Wegener's granulomatosis or microscopic polyangiitis according to the definitions of the Chapel Hill Consensus Conference
- Newly diagnosed patient of Wegener's granulomatosis or microscopic polyangiitis OR must be experiencing a disease flare characterized by: (a) active disease with a Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) of 3 or greater that would normally require treatment with CYC; OR (b) disease severe enough to require treatment with CYC; OR (c) must be positive for either PR3-ANCA (ANCA directed against proteinase 3) or MPO-ANCA (ANCA directed against myeloperoxidase)at the screening
- Willing to use acceptable forms of contraception for the duration of the study and for up to 1 year after stopping study medications
- Willing to report pregnancies (female participants or male participants' partners) occurring at any time during the study and for up to 1 year after stopping study medications
- Parent or guardian willing to provide informed consent, if applicable
Exclusion Criteria:
- Diagnosis of Churg-Strauss Syndrome according to the definitions of the Chapel Hill Consensus Conference
- Have limited disease that would not normally be treated with CYC
- Requires mechanical ventilation because of alveolar hemorrhage
- History of severe allergic reactions to human or chimeric monoclonal antibodies
- Active systemic infection
- Have a deep-space infection, such as osteomyelitis, septic arthritis, or pneumonia complicated by pleural cavity or lung abscess, within 6 months prior to study entry
- History of or current hepatitis B or C infection
- HIV (human immunodeficiency virus) infected
- Acute or chronic liver disease that, in the opinion of the investigator, may interfere with the study
- History of or active cancer diagnosed within the last 5 years. Individuals with squamous cell or basal cell carcinomas of the skin and individuals with cervical carcinoma in situ who have received curative surgical treatment may be eligible for this study.
- History of anti-glomerular basement membrane (anti-GBM) disease
- Other uncontrolled disease, including drug and alcohol abuse, that may interfere with the study
- Pregnancy or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00104299
| United States, Alabama | |
| University of Alabama | |
| Birmingham, Alabama, United States, 35294 | |
| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21224 | |
| United States, Massachusetts | |
| Boston University | |
| Boston, Massachusetts, United States, 02118 | |
| United States, Minnesota | |
| Mayo Clinic Foundation | |
| Rochester, Minnesota, United States, 55905 | |
| United States, New York | |
| Hospital for Special Surgery | |
| New York, New York, United States, 10128 | |
| United States, North Carolina | |
| Duke University | |
| Durham, North Carolina, United States, 27710 | |
| United States, Ohio | |
| The Cleveland Clinic | |
| Cleveland, Ohio, United States, 44195 | |
| Netherlands | |
| University Hospital Groningen | |
| Groningen, Netherlands, 9713 GZ | |
| Study Chair: | John H. Stone, MD, MPH | Johns Hopkins University | |
| Study Chair: | Ulrich Specks, MD | Mayo Clinic |
Study Data/Documents: Individual Participant Data Set
ImmPort study identifier is SDY91.
ImmPort study identifier is SDY91.
TrialShare study ID is ITN021AI.
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00104299 |
| Other Study ID Numbers: |
DAIT ITN021AI |
| First Posted: | February 25, 2005 Key Record Dates |
| Results First Posted: | August 25, 2011 |
| Last Update Posted: | April 21, 2017 |
| Last Verified: | March 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Participant level data and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal. |
|
ANCA Vasculitis Wegener's Granulomatosis microscopic polyangiitis |
ANCA-positive ANCA-associated ANCA-associated vasculitis MPA |
|
Granulomatosis with Polyangiitis Microscopic Polyangiitis Vasculitis Systemic Vasculitis Vascular Diseases Cardiovascular Diseases Lung Diseases, Interstitial Lung Diseases Respiratory Tract Diseases Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Skin Diseases, Vascular Skin Diseases Autoimmune Diseases Immune System Diseases Cerebral Small Vessel Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Prednisone Methylprednisolone Cyclophosphamide Rituximab Azathioprine Glucocorticoids Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating |